AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17587724 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (short-acting loop diuretic)
Number of subjects: 300
Study 17587724 — intervention group
Group type: EXPERIMENTAL
Intervention: Azosemide (long-acting diuretic)
Number of subjects: 300
Study 14985994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower trunk accelerations measured by a tri-axial accelerometer during overground walking
Number of subjects: 41
Study 12231488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 148
Study 12231488 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 148
Study 11305519 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5-mg tablet) plus glucose (10% infusion at 62.5 ml/h for 12 h)
Number of subjects: 0
Study 11305519 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose alone)
Number of subjects: 0
Study 9356038 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administration
Number of subjects: 10
Study 9356038 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (NO synthase inhibitor)
Number of subjects: 10
Study 9356038 — intervention group
Group type: COMPARATOR
Intervention: Combined infusion of insulin and norepinephrine (NE)
Number of subjects: 10
Study 7706591 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 19
Study 7706591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice ingestion
Number of subjects: 19
Study 7706591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute hydrochloric acid ingestion
Number of subjects: 19
Study 7706591 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 19
Study 3228174 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-retinoic acid
Number of subjects: 12
Study 3228174 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1812095 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 9
Study 1812095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study 1812095 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 9
Study 1812095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1000195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dextran 70 and pneumatic leggings
Number of subjects: 50
Study 1000195 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 31085097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 60
Study 31085097 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 60
Study 29276914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery with pulmonary artery ablation (ablation group)
Number of subjects: 30
Study 29276914 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery (comparison group)
Number of subjects: 30
Study 26927446 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP/BEV/VIN (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w + vinorelbine at 25 mg/m² on days 1 + 8, q3w)
Number of subjects: 600
Study 26927446 — intervention group
Group type: COMPARATOR
Intervention: CAP/BEV (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w)
Number of subjects: 600
Study 24632102 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluated speaking stressor
Number of subjects: 60
Study 24632102 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 22396446 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningeal dissemination (MD) detected by CSF cytomorphology
Number of subjects: 415
Study 22396446 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningeal dissemination (MD) detected by PCR
Number of subjects: 415
Study 22396446 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningeal dissemination (MD) detected by MRI
Number of subjects: 415
Study 22396446 — intervention group
Group type: EXPERIMENTAL
Intervention: MD+ patients
Number of subjects: 415
Study 22396446 — intervention group
Group type: EXPERIMENTAL
Intervention: MD- patients
Number of subjects: 415
Study 19602719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study 19602719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 800 mg
Number of subjects: 0
Study 19602719 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study 19602719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17251808 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% castor oil emulsion
Number of subjects: 53
Study 17251808 — intervention group
Group type: COMPARATOR
Intervention: 0.32% hypromellose solution
Number of subjects: 53
Study 14734438 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (combination regimens)
Number of subjects: 0
Study 12076220 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV by face mask plus standard medical therapy (n = 39)
Number of subjects: 81
Study 12076220 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (n = 42)
Number of subjects: 81
Study 9872357 — intervention group
Group type: EXPERIMENTAL
Intervention: High CDT group (CDT >20 U/l on admission)
Number of subjects: 66
Study 9872357 — intervention group
Group type: COMPARATOR
Intervention: Low CDT group (CDT <= 20 U/l on admission)
Number of subjects: 66
Study 9872357 — intervention group
Group type: EXPERIMENTAL
Intervention: High CDT group
Number of subjects: 66
Study 7597928 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity guided tasks
Number of subjects: 0
Study 7597928 — intervention group
Group type: COMPARATOR
Intervention: Size guided tasks
Number of subjects: 0
Study 2193792 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million I.U. streptokinase or 1.8 million I.U. urokinase or APSAC
Number of subjects: 13
Study 508881 — intervention group
Group type: EXPERIMENTAL
Intervention: Postalcoholics
Number of subjects: 0
Study 508881 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenics
Number of subjects: 0
Study 508881 — intervention group
Group type: EXPERIMENTAL
Intervention: Organics
Number of subjects: 0
Study 508881 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 508881 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular procedure
Number of subjects: 0
Study 508881 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular procedure
Number of subjects: 0
Study 31907294 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 52
Study 31907294 — intervention group
Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 52
Study 31065914 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hyperventilation instruction
Number of subjects: 46
Study 31065914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 46
Study 28535926 — intervention group
Group type: EXPERIMENTAL
Intervention: web intervention
Number of subjects: 322
Study 28535926 — intervention group
Group type: EXPERIMENTAL
Intervention: web intervention and nurse facilitated workshop
Number of subjects: 322
Study 28535926 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 322
Study 25948266 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI responses for intact and phase-randomized face stimuli
Number of subjects: 0
Study 25948266 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI responses in the right face-selective fusiform face area (FFA)
Number of subjects: 0
Study 25948266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic functional connectivity within the visual cortical network (bilateral FFA and bilateral LOC)
Number of subjects: 0
Study 24129613 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist co-treatment started on CD 2
Number of subjects: 617
Study 24129613 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist co-treatment started on CD 6
Number of subjects: 617
Study 21327806 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine 0.5 mg/kg
Number of subjects: 50
Study 21327806 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline 5 ml (control saline group)
Number of subjects: 50
Study 19145653 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 U of botulinum toxin type B (BTxb)
Number of subjects: 20
Study 19145653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17530689 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped OSCE assessment
Number of subjects: 95
Study 17530689 — intervention group
Group type: COMPARATOR
Intervention: Live OSCE assessment
Number of subjects: 95
Study 15143763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids provided to elderly individuals (15.3% of those needing them)
Number of subjects: 331
Study 15143763 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiometric diagnosis
Number of subjects: 331
Study 15143763 — intervention group
Group type: COMPARATOR
Intervention: Hearing loss assessment
Number of subjects: 331
Study 12506278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa (1.86 mg/kg/day, 4:1 ratio) with occlusion therapy
Number of subjects: 40
Study 12506278 — intervention group
Group type: COMPARATOR
Intervention: Placebo with occlusion therapy
Number of subjects: 40
Study 12506278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa and placebo groups
Number of subjects: 40
Study 9579000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programs (Abecedarian and CARE)
Number of subjects: 985
Study 9579000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programs (IHDP)
Number of subjects: 985
Study 9579000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programs
Number of subjects: 985
Study 7897117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA) (100 mg over 3 h)
Number of subjects: 5711
Study 7897117 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5711
Study 7897117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 5711
Study 2766722 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone-1mg/mestranol-50 micrograms formulations (1 + 50)
Number of subjects: 51
Study 2766722 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone-1mg/ethinyl estradiol-35 micrograms formulations (1 + 35)
Number of subjects: 51
Study 783197 — intervention group
Group type: EXPERIMENTAL
Intervention: ouabain (0.015 mg/kg body weight)
Number of subjects: 11
Study 783197 — intervention group
Group type: COMPARATOR
Intervention: Control (no ouabain administration)
Number of subjects: 11
Study 31057311 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 140
Study 29798076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline lavage
Number of subjects: 20
Study 29798076 — intervention group
Group type: COMPARATOR
Intervention: Normal saline lavage
Number of subjects: 20
Study 26729617 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 201
Study 26729617 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 201
Study 25199825 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 34
Study 21775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Defocused ESWT (100 impulses/cm at 0.1 mJ/mm) applied once after debridement
Number of subjects: 50
Study 21775883 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (burn wound debridement/topical antiseptic therapy) without ESWT
Number of subjects: 50
Study 20329656 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol HFA formulation at 12 microg
Number of subjects: 14
Study 20329656 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol HFA formulation at 24 microg
Number of subjects: 14
Study 20329656 — intervention group
Group type: COMPARATOR
Intervention: Reference formoterol HFA preparation
Number of subjects: 14
Study 17426090 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (1 mg/kg.d)
Number of subjects: 39
Study 17426090 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (2 mg/kg.d)
Number of subjects: 39
Study 17426090 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (1 mg/kg.d) and (2 mg/kg.d)
Number of subjects: 39
Study 17426090 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (highest dose groups)
Number of subjects: 39
Study 17426090 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3
Number of subjects: 39
Study 17426090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (estimated energy expenditure 42.4 +/- 3.7 kcal.kg(‐1).day(‐1), n = 8)
Number of subjects: 16
Study 15802369 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (32.3 +/- 0.6 kcal.kg(‐1).day(‐1), n = 8)
Number of subjects: 16
Study 15802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after single, 1-s-duration maximum voluntary ankle dorsiflexion contractions
Number of subjects: 16
Study 15802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group after 2 min of dynamic, repetitive ankle dorsiflexion exercise
Number of subjects: 16
Study 15802369 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group after 2 min of dynamic, repetitive ankle dorsiflexion exercise
Number of subjects: 16
Study 11802044 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg single dose of intramuscular injection of dexamethasone (n = 39)
Number of subjects: 118
Study 11802044 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg single dose of oral dexamethasone (n = 42)
Number of subjects: 118
Study 11802044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 118
Study 11802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (both forms)
Number of subjects: 118
Study 11802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (with identified bacterial pathogen, n = 47)
Number of subjects: 118
Study 11802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (without identified bacterial pathogen)
Number of subjects: 118
Study 9660161 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 6
Study 9660161 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study 7667171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine HCl 4 mg 4 times/day
Number of subjects: 6
Study 7667171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine HCl 8 mg 4 times/day
Number of subjects: 6
Study 7667171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2719760 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide, 400 mg capsules, twice a day for 60 days
Number of subjects: 50
Study 2719760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 57334 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 31
Study 31493279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Orofacial Test-Screening (NOT-S) in children with cerebral palsy
Number of subjects: 84
Study 31493279 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (control)
Number of subjects: 84
Study 31119404 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hyperventilation instruction
Number of subjects: 46
Study 31119404 — intervention group
Group type: COMPARATOR
Intervention: Control group without instruction
Number of subjects: 46
Study 28851310 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (post-diagnostic use)
Number of subjects: 6537
Study 28851310 — intervention group
Group type: COMPARATOR
Intervention: Other types of anticoagulants
Number of subjects: 6537
Study 28851310 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant non-users
Number of subjects: 6537
Study 28851310 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (pre-diagnostic use)
Number of subjects: 6537
Study 26316273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g instant decaffeinated coffee with 100 mg caffeine
Number of subjects: 10
Study 26316273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g instant decaffeinated coffee with 100 mg caffeine
Number of subjects: 10
Study 26316273 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g instant decaffeinated coffee with 100 mg caffeine
Number of subjects: 10
Study 26316273 — intervention group
Group type: COMPARATOR
Intervention: Control (400 ml water with 50 g glucose)
Number of subjects: 10
Study 23942682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 74)
Number of subjects: 225
Study 23942682 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of zonisamide (n = 76)
Number of subjects: 225
Study 21533629 — intervention group
Group type: COMPARATOR
Intervention: Diet plus placebo (group 1, n=16)
Number of subjects: 137
Study 21533629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus losartan (group 2, n=16)
Number of subjects: 137
Study 21533629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus enalapril (group 3, n=14)
Number of subjects: 137
Study 18298328 — intervention group
Group type: EXPERIMENTAL
Intervention: IP plus GP in SB
Number of subjects: 120
Study 18298328 — intervention group
Group type: COMPARATOR
Intervention: Common gamma probe (GP) in SA
Number of subjects: 120
Study 16737682 — intervention group
Group type: EXPERIMENTAL
Intervention: US-inflation manipulation (information manipulation and enhanced US)
Number of subjects: 0
Study 16737682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no US-inflation manipulation)
Number of subjects: 0
Study 14724725 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT)
Number of subjects: 35
Study 11054200 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine and 50 mg of ranitidine (active group)
Number of subjects: 91
Study 11054200 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of diphenhydramine and saline solution (control group)
Number of subjects: 91
Study 8764816 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 600 mg daily
Number of subjects: 60
Study 8764816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7962330 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulosa cells from anovPCO
Number of subjects: 64
Study 7962330 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulosa cells from ovPCO
Number of subjects: 64
Study 7962330 — intervention group
Group type: COMPARATOR
Intervention: Granulosa cells from normal ovaries
Number of subjects: 64
Study 7962330 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid from ovPCO
Number of subjects: 64
Study 7962330 — intervention group
Group type: COMPARATOR
Intervention: Follicular fluid from normal ovaries
Number of subjects: 64
Study 3113295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (180 microgram) administered 15 minutes prior to exercise
Number of subjects: 80
Study 3113295 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn (20 mg) administered 15 minutes prior to exercise
Number of subjects: 80
Study 3113295 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn (20 mg) administered 4 times/day for 2 or 4 weeks
Number of subjects: 80
Study 29472143 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh sacropexy (LS)
Number of subjects: 257
Study 24164537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and L-asparaginase (experimental arm)
Number of subjects: 310
Study 24164537 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cytarabine, oral 6-mercaptopurine, and cyclophosphamide (standard arm)
Number of subjects: 310
Study 23291141 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus cisplatin 25 mg/m² d1‐3 and 40 Gy of radiation therapy (Arm A)
Number of subjects: 154
Study 23291141 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 25 mg/m² d1‐3 plus fluorouracil 600 mg/m² d1 ∼ 5 and 40 Gy of radiation therapy (Arm B)
Number of subjects: 154
Study 20096753 — intervention group
Group type: EXPERIMENTAL
Intervention: gentle Continuous Punishment (gentle COP) policies
Number of subjects: 0
Study 18339420 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release oxybutynin 10 mg
Number of subjects: 60
Study 18339420 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine 200 mg
Number of subjects: 60
Study 18339420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15634033 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine 400mg three times daily
Number of subjects: 234
Study 15634033 — intervention group
Group type: EXPERIMENTAL
Intervention: N-delavirdine
Number of subjects: 234
Study 15634033 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine
Number of subjects: 234
Study 12711838 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC 600 mg/day
Number of subjects: 40
Study 12711838 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC 1,800 mg/day
Number of subjects: 40
Study 12711838 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC 1,800 mg/day (after washout period)
Number of subjects: 40
Study 12711838 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (both dosages)
Number of subjects: 40
Study 12711838 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group A)
Number of subjects: 40
Study 10234397 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 90
Study 10234397 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg/kg
Number of subjects: 90
Study 8527619 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg in the early evening
Number of subjects: 276
Study 8527619 — intervention group
Group type: COMPARATOR
Intervention: roxatidine 150 mg at bedtime
Number of subjects: 276